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ABSTRACT
Clinical trials published over the last 
5 years support the main conclusion of 
a comprehensive review on glucocorti-
coid safety published in 2006: there is 
little if any solid evidence to support 
the fear that low-dose glucocorticoids 
are associated with signiﬁcant toxicity 
when used appropriately in inﬂamma-
tory rheumatic diseases. In fact, most 
of the recent randomised-controlled 
research underlines the inﬂuence of the 
underlying inﬂammatory process in the 
occurrence of “adverse events” such as 
osteoporosis, fractures, hypertension 
and glucose intolerance. This “con-
founding by indication” is inherent to 
the ﬁeld and questions the validity of 
the observational data, that seems to 
drive currently common concepts about 
low-dose glucocorticoid toxicity. Deci-
sive conclusions cannot, in any case, 
be achieved at this stage because the 
clinical trails available are of limited 
duration and dimension and have not 
been designed speciﬁcally to address 
toxicity.
Toxicity with low-dose glucocorticoids 
needs to be kept under careful clinical 
surveillance while we expect such trials 
to be produced. Meanwhile, the risks 
of stopping these medications, even on 
longstanding well controlled disease, 
need also to be considered, as under-
lined by withdrawal trials recently pub-
lished.
Introduction
In 2006, we reported the results of an 
extensive review of the toxicity of low-
dose glucocorticoids (GCs) in rheu-
matoid arthritis (RA), including un-
published data from four randomised 
clinical trials (1). The review was fo-
cused on RA, but publications regard-
ing other conditions were also reviewed 
and integrated. The interpretation was 
submitted to consensus among all co-
authors as cooperating experts.
Two main general conclusions were de-
rived from this comprehensive work:
• “Few of the commonly held beliefs 
about the incidence, prevalence, and 
impact of glucocorticoid side-effects 
are supported by clear scientiﬁc evi-
dence”. 
• “Safety data from recent randomised 
controlled clinical trials of low-dose 
glucocorticoid treatment in RA sug-
gest that adverse effects associated 
with these drugs are modest, and 
often not statistically different from 
those of placebo”.
Taking all available information togeth-
er the expert panel felt that the evidence 
for increased risk of adverse effects 
with low-dose GCs was strong enough 
to justify regular checks on some: oste-
oporosis, Cushingoid symptoms, adre-
nal crisis on glucocorticoid withdrawal, 
growth retardation in children, new on-
set of diabetes mellitus in subjects at risk 
or worsening of glycaemia control in 
patients with the disease, cataracts and 
glaucoma, peptic ulcer (in combination 
with NSAIDs) and hypertension. The 
panel considered that many (if not most) 
of the side-effects commonly attributed 
to GCs, such as myopathy, psychosis, 
hyperlipidemia, and atherosclerosis, 
were probably very rare, if observed at 
all, with low-dose therapy. 
This may seem an over-optimistic per-
spective. It is fair to recognise that such 
conclusions were based more on the 
absence of evidence for a connection 
than on reassuring evidence that such a 
connection does not exist. Recognising 
this, the report underlined the paucity 
of good quality evidence, and did not 
conclude that low-dose GCs are safe 
but rather that “The overall fear of GC 
toxicity in RA, as quoted in textbooks 
and review articles, is probably over-
estimated, based on extrapolation from 
observations with higher dose treat-
ment”. 
Most of these fears are rooted in obser-
vational data, with a variety of doses 
and regimens, in a variety of different 
diseases. Very little actually is support-
ed in clinical trials.
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Observational studies in this area are 
bound to reﬂect confounding by indica-
tion, which may undermine the validity 
of their results. In fact, many inﬂam-
matory rheumatic diseases are, per se, 
associated with an increased incidence 
of conditions that have been considered 
side-effects of the GCs used to treat 
them. Rheumatoid arthritis, independ-
ently of GCs, is recognised as a very 
signiﬁcant risk factor for cardiovascu-
lar disease (2, 3), hypertension (4, 6), 
osteoporosis and fractures (6, 7) and 
decreased insulin sensitivity (8). In 
fact, there is overwhelming evidence 
that chronic inﬂammatory diseases in 
general are associated with a signiﬁcant 
increase in cardiovascular risk which 
seems mediated mostly by the inﬂam-
matory process itself (9). The same is 
probably true for osteoporosis (10). A 
recent study found a surprising preva-
lence of 7% of vertebral fractures in 
children with a variety of auto-immune 
rheumatic diseases before starting GCs 
treatment (11). Manifestations of sys-
temic lupus erythematosus (SLE) have 
even more in common with potential 
toxicity of GCs: atherosclerosis, hyper-
tension, osteoporosis, psychosis, my-
opathy, aseptic bone necrosis.  
Therefore, rheumatic inﬂammatory dis-
eases carry an increased risk of these 
adverse events and will also be asso-
ciated with an increased probability of 
GC use, which is also associated with 
the adverse outcome. Higher severity 
of disease implies higher risk of such 
events, and also a higher probability of 
GC use and in higher doses. It may be 
that the suppressing effect of GCs on 
disease activity may actually dimin-
ish the incidence of the adverse event 
compared to what would be observed 
in its absence. However, the risk may 
still be higher than would be seen in the 
absence of disease or in the presence of 
disease that is milder than considered 
necessary to warrant GCs. In such cas-
es, observational studies would suggest 
that GCs are doing harm even if they 
are actually reducing the risk induced 
by the underlying condition. 
Separating the inﬂuence of the disease 
from that of GCs is an impossible task 
for observational studies at their current 
stage of methodological development: 
we can never be sure that all relevant 
confounding factors have been consid-
ered in multivariate analysis – only the 
ones we are aware of! Observational 
studies are certainly essential to iden-
tify concerns of toxicity, especially 
those associated with long-term thera-
py. However, a deﬁnite clariﬁcation of 
the role of medication versus co-factors 
can only be achieved through clinical 
trials where randomisation overcomes 
potential confounding introduced by 
disease severity and other variables af-
fecting the prescription and its effects. 
Moreover, a deﬁnite trial would need 
to be focused on toxicity (rather than 
on efﬁcacy), adopt a strict and stand-
ardised strategy for identiﬁcation and 
registry of side-effects and be of suf-
ﬁcient size and duration to allow for 
the importance of time and cumulative 
dose to be reﬂected. Despite the pub-
lication of recommendations for the 
design of clinical trails on GCs (12), 
no such a trial has been published and, 
until then, deﬁnitive conclusions on the 
real toxicity of low-dose GCs cannot 
be reached.
We scrutinised relevant information 
from clinical trials and experimental 
studies published in the six years since 
the preparation of our previous report 
(1). 
General scope of toxicity
A randomised clinical trial, which 
would have achieved the inclusion cri-
teria for that review, was published just 
after the work was ﬁnished (13). In this 
study, 250 patients with early RA were 
randomised to receive, at the start of 
their initial treatment with a disease-
modifying drug, either 7.5 mg/day 
prednisolone or no prednisolone for 2 
years. The results conﬁrmed signiﬁcant 
beneﬁts of this low-dose GCs therapy, 
both in terms of disease activity and 
radiographic progression. The authors 
concluded that this treatment was safe, 
with very few adverse events leading 
to withdrawal in both groups. These 
general conclusions are coincident 
with the trials included in our 2006 
review. And the same holds true when 
it comes to speciﬁc adverse effects: 
drug treatment was withdrawn tem-
porarily or permanently in 26 patients 
in the prednisolone group and in 24 
patients in the no-prednisolone. Most 
withdrawals were attributed to the as-
sociated DMARD, and prednisolone 
was judged to be the cause in 5 patients 
only: one withdrawal due to each of the 
following causes – diabetes, proteinu-
ria, striae and ecchymoses, weight gain 
and cushingoid appearance, and weight 
gain. It is worth noting that 110 of the 
119 patients allocated to prednisolone 
persisted on this therapy for the two 
years of the trial duration. 
Similarly reassuring results were found 
in the CARDERA trial (14). Four hun-
dred and sixty-seven patients with RA 
were randomised to receive prednisolo-
ne (initial dose 60 mg/day tapered at 
34 weeks) in addition to MTX with or 
without cyclosporine. GCs were as-
sociated with signiﬁcant beneﬁts in 
terms of disease activity and erosions 
over two years of follow-up, without 
“signiﬁcant differences in serious ad-
verse events between the groups”. In 
this study, GCs therapy was, however, 
associated with a signiﬁcant increase 
in the risk of developing hypertension 
(OR: 2.16) and with a more pronounced 
bone loss at the hip.
Limited data on toxicity of high-dose iv 
pulse methylprednisolone (IV MP) was 
offered by a trial (15) of 44 RA patients 
randomised to receive methotrexate 
(MTX), alone or in combination with 
IV MP (1000 mg) or inﬂiximab on day 
0 and weeks 2, 6, 14, 22, 30, 38, and 46. 
This is, to our knowledge, the longest 
trial of pulsed GCs in RA, with a daily-
dose of over 30 mg prednisolone-equiv-
alent/day: most clinicians would expect 
serious toxicity. The rate of remission 
was similar with IV MP and inﬂixi-
mab and signiﬁcantly superior to MTX 
alone. Regarding safety, the authors 
summarise in stating that treatment was 
generally very well tolerated and no se-
vere side effects were observed, except 
1 case of MTX-related pneumonitis. 
The rate of infections was similar in the 
three groups.
Osteoporosis
Trials published on GCs are too small 
and/or short in duration to allow deﬁni-
tive conclusions regarding osteoporosis 
and, especially, fractures. However, the 
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results of all these RCTs show a much 
lower rate of GCs-induced bone loss 
than would be expected from current 
general reviews and recommendations.
In the BARFOT study, discussed above 
(12), there was no difference in bone 
loss between those receiving 7,5mg/day 
prednisolone over two years and those 
who did not! This was further analysed 
in 150 patients with markers of bone 
metabolism (16). The authors conclud-
ed that low-dose prednisolone actually 
avoided bone loss induced by rheuma-
toid inﬂammation at the hip. This was 
not observed on the spine where a 
small but signiﬁcant negative impact 
of prednisolone on vertebral BMD was 
observed in this subgroup (not signiﬁ-
cant in the overall population). A strong 
positive correlation was found between 
bone resorption markers and disease 
activity, as indicated by CRP and IL-6, 
emphasising the importance of inﬂam-
mation in osteoporosis. 
Similar results have been reported from 
the BeSt trial (17) – the combination 
strategy including highdose GCs was 
not associated with increased bone loss 
over one year in early RA. Also in this 
study, joint damage and joint damage 
progression were associated with high 
BMD loss. 
Such observations emphasise the link 
between disease activity and general-
ised bone loss. These observations un-
derline the need for caution when inter-
preting the cause of bone loss observed 
in the presence of GCs.
Strategies to prevent glucocorticoid- 
induced osteoporosis have been recently 
reinforced with the demonstration that 
yearly zoledronic acid (18) is an efﬁ-
cient alternative. The results with pras-
terone in SLE were less optimistic (19).
Cardio-vascular and glucose 
metabolism
Analysis of data from the BeSt trial 
offers some interesting insights into 
the relationship between rheumatoid 
arthritis, GCs and hypertension (4). 
Results show a striking positive cor-
relation between indices of disease 
activity and levels of both systolic and 
diastolic blood pressure, not only at 
baseline but throughout the two years 
of the study. The group receiving com-
bination therapy including high-dose 
prednisolone did not show a tendency 
towards higher blood pressure. Actu-
ally, the diastolic blood pressure was 
signiﬁcantly reduced in this group, 
compared to sequential monotherapy. 
Interestingly, the use of anti-TNF stood 
out with a remarkable beneﬁcial ef-
fect upon blood pressure, exceeding 
the improvement expected on the basis 
of disease activity alone. Such obser-
vations again suggest the existence of 
important interactions between the in-
ﬂammatory response, blood pressure 
regulation and cardio-vascular risk.
The impact of GCs upon atheroscle-
rosis and endothelial function in pa-
tients with concomitant inﬂammatory 
disease was addressed in a subset of 
67 patients within the BARFOT study 
referred above (20). In the prednisolo-
ne group, 21 patients were treated for 
2 years and 13 continuously for ﬁve 
years before vascular evaluation (inti-
ma-media thickness, intima-media area 
and atherosclerotic plaque formation of 
the carotid and ﬂow-mediated dilation 
of the brachial artery). Neither of these 
measures differed between patients 
treated with and without prednisolone. 
Prednisolone was, in this trial, associ-
ated with higher levels of total choles-
terol and a trend towards higher blood 
pressure (for treatment longer than 
4 years). Age, blood pressure, HDL 
cholesterol and creatinine were corre-
lated with the vascular parameters. The 
impact of disease activity was not ad-
dressed in this report. 
A very elegant study, now in press (8), 
demonstrates that RA disease activity 
is strongly related with abnormalities 
in glucose metabolism, irrespective of 
GCs. Cumulative dose of GCs also had 
an independent negative effect on glu-
cose tolerance and insulin sensitivity.
Infection
A systematic literature review looked 
at the evidence regarding the risk of in-
fection associated with low-dose GCs 
(≤10mg/day prednisolone equivalent) 
in RA (21). Of the 1310 screened re-
ports, the literature analysis identiﬁed 
15 eligible reports. Of the eight reports 
that studied all types of infection, six 
articles found no association between 
risk of infection and low-dose GCs. 
One of the reports described a signiﬁ-
cant association severe infections (OR 
= 8 [1–64]) and another indicated a 
dose-dependent association: RR = 1.32 
for doses <5 mg/day 1.95 for doses be-
tween 6 to 10 mg/day. 
Of three trials evaluating the risk of 
bacterial infection: one showed an in-
creased risk (HR = 1.7 [1.5–2.0]) while 
two did not, in doses up to 10mg/day.
None of three trials studying postoper-
ative infection risk nor any of the two 
reports looking at herpes zoster found 
a signiﬁcant association between infec-
tion risk and low-dose GCs. The au-
thors of this systemic literature review 
stress the scarcity of good quality data 
preventing sound conclusions. 
However, their results are globally in 
line with the conclusion of a meta-
analysis of 71 trials involving about 
2000 patients with various underlying 
diseases: GCs exposure was associated 
with an overall relative risk of infec-
tion of 1.6 (22) but the risk was not 
signiﬁcantly increased with doses be-
low 10 mg/day, especially in rheumatic 
diseases. 
Chronotherapy
The studies on the newly developed 
modiﬁed release tablets for prednisolo-
ne, have not added signiﬁcantly to our 
knowledge on the safety of GCs be-
cause there was no placebo-group in 
the trials. These tablets allow the medi-
cation to be released in the GI tract at 
about 2 am, if taken orally at around 10 
pm, thus delivering the drug at the time 
when circulating endogenous glucocor-
ticoids are at their lowest levels and in-
ﬂammatory mediators, such as IL-6 are 
at their highest. Of note, the fact that 
night-time prednisone over 12 months 
did not induced signiﬁcant changes in 
the corticotropin-releasing-hormone test 
in comparison to immediate release 
prednisone administered in the morn-
ing (23). Such observations indicate 
that prednisolone need not be given in 
the morning to avoid the risk of serious 
unbalance of the HPA axis. The overall 
safety proﬁle was found to be similar 
between both preparations in a 13-week 
trial whose primary endpoint was dura-
tion of morning stiffness (24).
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Osteonecrosis
Osteonecrosis has been considered a 
rather common side-effect of GCs, es-
pecially in SLE. An interesting trial 
including 60 newly diagnosed SLE pa-
tients (25) suggests that warfarin may 
reduce by around 30% the incidence 
of osteonecrosis of the femoral head 
(ONF) induced by high-dose GCs. Al-
though the rate of osteonecrosis seems 
extremely high in this study (33% of 58 
control hips over ﬁve years), the results 
offer hope that such a serious adverse 
event can be partially prevented. 
The adverse effects of stopping GCs
Common wisdom and even authorita-
tive recommendations (26) suggest 
that GCs should be used for the lowest 
possible dose and tapered as soon as 
possible. Although the same argument 
could be presented to every single drug 
in every single medical condition, it is 
interesting that GCs seem to deserve it 
much more than any other medication. 
This, obviously, reﬂects the fear of side 
effects but it also incorporates some 
disregard for the positive effects of 
GCs. Stopping GCs has a cost: the loss 
of beneﬁt, including well-established 
disease modiﬁcation in RA. This has 
been overcome in most reviews by the 
statements that: 1. The beneﬁts of GCs 
are short lived and 2. Stopping GCs is 
followed by a rebound ﬂare. The latter 
argument is strange: Most clinicians 
would agree that disease aggravation 
after stopping a given drug is a sign that 
it was working! Do we ever question 
this with any other drug but GCs? 
The former argument has been clearly 
dismissed by objective evidence of ef-
ﬁcacy of longterm low-dose GCs in 
RA, in randomised withdrawal trials. 
In the report by Tengstrand et al. (27), 
ﬁfty-eight patients with RA treated with 
5–7.5 mg prednisolone daily for at least 
2 years were randomised either to with-
draw or to continue GC treatment. The 
patients were followed prospectively for 
2 years with respect to disease activity, 
functional ability and bone mineral den-
sity of the lumbar spine and hip. 15 of 
the 26 patients failed to withdraw GC 
because of increased disease activity and 
deteriorating function. A higher mean 
DAS28 during the study (as observed in 
those who tried and failed to stop GCs) 
was associated with loss of bone mass 
in the trochanter. The group that con-
tinued with unchanged GC treatment 
did not deteriorate in BMD during the 
2 years: in fact their Z-scores improved 
signiﬁcantly. It is probable that these 
good results on BMD were favoured by 
supplementation with calcium and vita-
min D. Pincus et al. (28), also found that 
stopping longterm GCs (used in stable 
doses of 1 to 4 mg/day in patients with 
stable controlled disease), was followed, 
in a large proportion of patients, by in-
creased inﬂammatory activity.  
Taken together, the results of these two 
trials suggest that tapering or withdraw-
ing GC treatment is not an obligatory 
path: the decision must take into consid-
eration the risks as well as the beneﬁts 
of continuing the medication for the in-
dividual patient. Withdrawal should not 
be forced at the cost of higher disease 
activity and all the associated adverse 
consequences associated with it.
Clinicians may also wish to consider, 
in this setting, recent suggestions that 
longterm GC use is associated with a 
reduced risk of lymphoma in RA (29).
Conclusions
The evidence to support clear conclu-
sions regarding the toxicity of GCs 
remains limited in quantity and, espe-
cially, in quality. Although RCTs are 
indispensible to avoid the confounding 
by indication that inevitably degrades 
the validity of observational studies, 
they also have limitations, in terms of 
duration, inclusion criteria and, above 
all, lack of focus and methodological 
rigor regarding toxicity. However, this 
is the best evidence we have, and, as far 
as low-dose therapy, it looks a lot more 
reassuring than current medical opinion 
would suggest. 
These are, nevertheless, questionable 
data and interpretations, and deﬁnite 
conclusions will not be possible before 
properly designed trials focused on 
safety issues are available.
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